One year after replacement with zoledronate, reversals of denosumab’s gains in lumbar spine BMD are seen — with longer ...

Tom Nolan reviews this week’s research Many people with osteoporosis are unable to tolerate oral bisphosphonates—many others would prefer a six monthly denosumab injection to a once weekly pill that ...

The risk for emergently treated hypocalcemia in individuals receiving denosumab peaked at 2 weeks after administration and ...

Denosumab treatment for osteoporosis appears more hazardous in postmenopausal women with advanced chronic kidney disease (CKD).

USA: A target trial emulation study revealed that denosumab significantly increased the risk of hypocalcemia requiring ...

Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases ...

In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment as compared with bisphosphonates among women with osteoporosis in the ...

Amgen's osteoporosis drug, Prolia (denosumab), could have a new use after it showed positive results in glucocorticoid-induced disease. Prolia is already well established, with sales of more than ...